Results 121 to 130 of about 78,820 (216)

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source

RETRACTION: Dietary Valine Ameliorated Gut Health and Accelerated the Development of Nonalcoholic Fatty Liver Disease of Laying Hens. [PDF]

Oxid Med Cell Longev
Cellular Longevity OMA.
europepmc   +1 more source

Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug‐Induced Liver Injury

Hepatology Research, EarlyView.
Three metabolites, pyroglutamylglycine (pyroGluGly), phenylalanine (Phe), and phenylalanyltryptophan (PheTrp), were identified as candidate DILI biomarkers. The serum concentrations of pyroGluGly, Phe, and PheTrp demonstrated a high differentiating ability in patients with mixed and cholestatic DILI compared with those in patients who recovered from ...
Kosuke Saito, Tatehiro Kagawa, Keiji Tsuji, Yuji Kumagai, Ken Sato, Shotaro Sakisaka, Naoya Sakamoto, Mitsuhiko Aiso, Shunji Hirose, Nami Mori, Toshio Uraoka, Kazuhide Takata, Koji Ogawa, Kazuhiko Mori, Motonobu Sato, Takayoshi Nishiya, Kazuhiko Takamatsu, Noriaki Arakawa, Takashi Izumi, Ruri Kikura‐Hanajiri, Yasuo Ohno, Yoshiro Saito, Hajime Takikawa   +22 more
wiley   +1 more source

A critical review of natural products driven correction of bile acid dysregulation: a therapeutic strategy for nonalcoholic fatty liver disease. [PDF]

Front Pharmacol
Peng Q, Hao L, Li S, Yu F, Li N, Hu X.
europepmc   +1 more source

Metabolic Health Phenotypes Among Middle‐ to Older‐Aged Adults Living With and Without Obesity: Relationships With Hepatic Health Indicators

Hepatology Research, EarlyView.
We examined liver health indicators among obese and nonobese metabolic health phenotypes. In fully adjusted models, higher fatty liver index (FLI) scores and liver enzyme concentrations of gamma‐glutamyl transferase (GGT) and alanine aminotransferase (ALT) were associated with lower likelihood of metabolically healthy obese (MHO) and nonobese (MHNO ...
Grainne Dolan, Seán R. Millar, Ivan J. Perry, Catherine M. Phillips   +3 more
wiley   +1 more source

Comment on "Development and Validation of Machine Learning-Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease". [PDF]

Adv Sci (Weinh)
Peng H, Duan S.
europepmc   +1 more source

Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders

Hepatology Research, EarlyView.
It is speculated that the onset of obesity‐related diseases follows the sequence of obesity → SLD → MetS‐related diseases. In this study, the contribution of SLD to each MetS‐related disease was large for T2D and hypertension and SLD contributed to the onset and new onset of the disease by the 7‐year follow‐up.
Yoshihiro Kamada, Makoto Fujii, Hitoshi Nishizawa, Shiro Fukuda, Makoto Yamada, Iichiro Shimomura, Eiji Miyoshi   +6 more
wiley   +1 more source

Mediating Role of BMI in the Association Between Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Mediation Analysis. [PDF]

Can Respir J
Luo Z, Shu L, Yu W.
europepmc   +1 more source

Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

Journal of Diabetes Investigation, EarlyView.
Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement.
Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki   +4 more
wiley   +1 more source

Impact of Change, Fluctuation, or Variability in Weight on the Risk of Nonalcoholic Fatty Liver Disease in General Population: A Systematic Review and Meta-Analysis. [PDF]

Health Sci Rep
Alijanzadeh D, Noroozi M, Rostami N, Norouzkhani N, ShojaeiBaghini M, Lashkajani SZ, Mirzaei A, Dianati M, Salimi M, Sadeghsalehi H, Jadidian F, Ghane Ezabadi S, Fallahi MS, Fathi M, Alizadeh A, Anar MA, Deravi N.   +16 more
europepmc   +1 more source